DeciBio Insights

DeciBio News: Introducing new partner, Andrew Aijian, PhD

Company News

DeciBio is pleased to introduce the company’s newest Partner, Andrew Aijian, PhD. In promoting Andrew to Partner, DeciBio Consulting announces its first addition to the Partnership since its formation.

At DeciBio, Andrew advises clients on the research tools and diagnostic activities, strategies, and opportunities accompanying the emergence of cancer immunotherapies and has actively expanded DeciBio’s pharma and biotech practice.  Andrew has led projects across a wide variety of segments within the research tools and clinical diagnostics landscapes, including, among others, infectious disease diagnostics, health IT, translational pathology, genomics instruments and reagents, proteomics research tools, and oncology diagnostics and biomarkers.  He has also contributed to multiple market research reports, developed DeciBio’s clinical trial biomarker analysis platform (BioMAP), and advised on the spin-out of DeciBio Analytics — DeciBio’s data analysis and market intelligence tools unit.

According to Founding Parter, Stephane Budel, “As one of our earliest employees, Andrew has been integral to the growth and development of DeciBio’s business and culture.  We describe ourselves as a meritocracy, and his path to Partnership is a testament to the fact that anyone can chart their own course here. I’m happy and excited to count him as a friend and business partner.”

Andrew credits the entrepreneurial nature of the firm as crucial to his development, “From day one I was given the opportunity and responsibility to push myself, not only to lead client engagements but also to contribute to the growth of the firm.  I’ve appreciated the trust, support, and mentorship I’ve received from the DeciBio Partners over the years, and I look forward to continuing to establish this firm as a leader in life-science consulting.”

Andrew received a Ph.D. in Biomedical Engineering from UCLA and a B.S. in Chemical and Biomolecular Engineering from the University of Notre Dame.  He joined DeciBio as a Ph.D. intern in 2013 and became a full-time employee in 2014.

RELATED ARTICLES

I/O Biomarker Spotlight: Digital Pathology and Multiplex Spatial Tissue Analysis

Pulse Survey: Adoption and Utilization of Next Generation Cancer Biomarkers

Contact us for more information about DeciBio's precision medicine strategy and market intelligence capabilities.